mProX™ Human MAP3K1 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Jessica
Verified Customer
Deborah
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 Transfection of Map3k1 amiRNA significantly impaired cellular level of MEKK1.
4T1 cells were transfected using the constructs. The highest interference efficiency was attained by Map3k1 amiRNA-3 by real-time PCR analysis. The transfection of Map3k1 amiRNA-3 resulted in a significant down-regulation of the MEKK1 protein level, as anticipated.
Ref: Liu, Chun, et al. "MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro." Springerplus 5 (2016): 1-12.
Pubmed: 26759750
DOI: 10.1186/s40064-015-1597-z
Research Highlights
Numerous sex-determining genes have been found through research into diseases of sex development (DSD). Encoding a signal transduction regulator in the process of sex determination, MAP3K1 is becoming known as one of the more prevalent genes causing 46,XY DSD, which manifests as either total or partial gonadal dysgenesis.
Granados, Andrea, et al. "MAP3K1-related gonadal dysgenesis: Six new cases and review of the literature." American Journal of Medical Genetics Part C: Seminars in Medical Genetics. Vol. 175. No. 2. 2017.
Pubmed:
28504475
DOI:
10.1002/ajmg.c.31559
In luminal A BrCa samples, activating mutations of PIK3CA (~45%) are commonly seen. In luminal A BrCa samples, genomic analyses have revealed inactivating mutations in two upstream kinases of the JNK apoptotic pathway, MAP3K1 (13-20%) and MAP2K4 (~8%).
Avivar-Valderas, Alvaro, et al. "Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer." Oncotarget 9.30 (2018): 21444.
Pubmed:
29765551
DOI:
10.18632/oncotarget.25118